Impact of changed co-amoxiclav susceptibility testing formats on apparent resistance rates for bloodstream Escherichia coli in a long-term surveillance

J Antimicrob Chemother. 2022 Mar 31;77(4):1206-1208. doi: 10.1093/jac/dkab483.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amoxicillin-Potassium Clavulanate Combination
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia* / drug therapy
  • Drug Resistance, Bacterial
  • Drug Resistance, Multiple, Bacterial
  • Escherichia coli / genetics
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli Infections* / epidemiology
  • Humans
  • Microbial Sensitivity Tests

Substances

  • Anti-Bacterial Agents
  • Amoxicillin-Potassium Clavulanate Combination